Tânia P Salci1,2, Melyssa Negri1, Ana Karina R Abadio3, P Bonfim-Mendonça1, Isis Capoci1, Silvana M Caparroz-Assef4, Lucélia Donatti5, Maria Sueli S Felipe6, Erika S Kioshima1, Terezinha Ie Svidzinski1. 1. Universidade Estadual de Maringá, Medical Mycology, Av Colombo, 5790 - Zona 7, Maringá - PR 87020-900, Brazil. 2. Faculdade Integrado, Department of Pharmacy - Campo Mourão, Av José C de Oliveira, 1325 - Centro, Campo Mourão, PR 87300-020, Brazil. 3. Universidade do Estado de Mato Grosso, Department of Biology, Av dos Ingás, 3001 - Jardim Imperial, Sinop - MT 78555-000, Brazil. 4. Universidade Estadual de Maringá, Department of Pharmacology and Therapeutics, Av Colombo, 5790 - Zona 7, Maringá - PR 87020-900, Brazil. 5. Universidade Federal do Paraná, Department of Cellular Biology, Rua XV de Novembro, 1299 - Centro, Curitiba - PR 80060-000, Brazil. 6. Universidade de Brasília, Department of Cellular Biology, Campus Universitário Darcy Ribeiro, Brasília - DF 70910-900, Brazil.
Abstract
AIM: To investigate the antifungal activity of MOL3, a small molecule that was selected by virtual screening, against Candida spp. MATERIALS & METHODS: The antifungal activity of MOL3 was evaluated using standard strains and clinical isolates. Activity was evaluated in both in vitro tests and animal models. RESULTS: The minimum fungicidal concentration of MOL3 against Candida spp. ranged from 16 to 128 mg/l. MOL3 at the sub-minimum fungicidal concentration inhibited hyphal elongation. The remaining yeast cells presented morphological changes and were metabolically inactive. MOL3 was toxicologically inert both in vitro and in the animal model. MOL3 also reduced experimental systemic infection by C. parapsilosis in mice. CONCLUSION: The selection of MOL3 by virtual screening was successful, revealing a promising antifungal candidate.
AIM: To investigate the antifungal activity of MOL3, a small molecule that was selected by virtual screening, against Candida spp. MATERIALS & METHODS: The antifungal activity of MOL3 was evaluated using standard strains and clinical isolates. Activity was evaluated in both in vitro tests and animal models. RESULTS: The minimum fungicidal concentration of MOL3 against Candida spp. ranged from 16 to 128 mg/l. MOL3 at the sub-minimum fungicidal concentration inhibited hyphal elongation. The remaining yeast cells presented morphological changes and were metabolically inactive. MOL3 was toxicologically inert both in vitro and in the animal model. MOL3 also reduced experimental systemic infection by C. parapsilosis in mice. CONCLUSION: The selection of MOL3 by virtual screening was successful, revealing a promising antifungal candidate.
Authors: Erika Seki Kioshima; Patrícia de Souza Bonfim de Mendonça; Marcus de Melo Teixeira; Isis Regina Grenier Capoci; André Amaral; Franciele Abigail Vilugron Rodrigues-Vendramini; Bruna Lauton Simões; Ana Karina Rodrigues Abadio; Larissa Fernandes Matos; Maria Sueli Soares Felipe Journal: J Fungi (Basel) Date: 2021-02-02